冠心病、高血压患者血浆P物质水平的临床观察

方法 选择符合WHO诊断标准的急性心肌梗塞(AMI)20例,心绞痛(AP)30例,高血压病(EH)30例,应用放射免疫分析法动态观察血浆P物质(SP)含量变化,并以30例正常人作对照。结果冠心病(CHD)对照组SP水平为126.99±15.96pg/ml,AMI组发病第1天SP含量为62.85±16.76pg/ml,显著低于对照组(P<0.01)。发病第7天开始升高为72.60±15.20pg/ml,第21天趋于正常,为110.10±27.95pg/ml,与对照组比较无显著差异(P>0.05)。AP组心绞痛发作期SP含量为48.38±12.92pg/ml,显著低于对照组(P<0.001),经治疗2周症状缓解后复查血浆SP含量升高至78.70±9.15pg/ml,前后比较有显著差异(P<0.001)。EH组SP含量为59.75±17.89pg/ml,明显低于对照组(126.99±15.96pg/ml,P<0.001),EH的病情越严重,血浆SP的含量降低越明显。结论 循环血中SP含量不足可能是引发CHD、EH的重要因素之一;SP参与了CHD及EH的发病机理及病理生理过程。

Clinical study of plasma SP level in patients with coronar heart disease and essential hypertensin

Objective To investigate the changes of plasma substance P in patients with coronary heartdisease and hyperten sion. Methods The changes of plasma substance P(SP) level were observed by RIA in 20 patients with acute myocardial infarction ( AMI) , 30 with angina pectoris (AP) and 30 with essential hypertension (EH). Results The plasma SP level was 126. 99± 15. 96 pg/mL in the normal control group(30 healthy persons) .whereas it was 62. 85± 16. 76pg/ml in AMI patients during the first day of onset(p<0. 001). It began to increase from the 7th day and reached the normal value at the 21st day (110. 10±27. 95pg/mL). The plasma SP level was 48. 38± 12. 92pg/ml in AP patients during angina attack and was significantly lower than that of the normal group(p< 0. 001). After two weeks' treatment, it increased to 78. 70±9.15pg/mL(p<0. 001). The plasma SP level was 59. 75± 17. 89pg/mL in patients with EH and was significantly lower than that of the normal group(p<0. 001). Conclusions It was found that the increase of plasma SP level, was closely related with the severity of hypertension. It is suggested that t he decrease of plasma SP level may play an important role in pathogenesis of coronary heart disease and EH.